Items where authors include "Jackson, G."

Article

Pawlyn, C. orcid.org/0000-0002-7190-0028, Schjesvold, F.H. orcid.org/0000-0003-1096-0569, Cairns, D.A. orcid.org/0000-0002-2338-0179 et al. (13 more authors) (2024) Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm. Blood Cancer Journal, 14. 134.

Bui, M., Adjiman, C.S., Bardow, A. et al. (27 more authors) (2018) Carbon capture and storage (CCS): the way forward. Energy and Environmental Science, 11 (5). pp. 1062-1176. ISSN 1754-5692

Proceedings Paper

Dawkins, B., Gkountouras, G., Meads, D. et al. (21 more authors) (2024) Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07-10 Dec 2024, San Diego, USA. American Society of Hematology , pp. 385-386.

Cook, G., Pawlyn, C., Royle, K.-L. et al. (20 more authors) (2024) IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07 Dec 2024, San Diego, USA. American Society of Hematology , pp. 673-674.

Reed, M., Cairns, D.A. orcid.org/0000-0002-2338-0179, Pawlyn, C. et al. (13 more authors) (2023) The Impact of Epstein-Barr Virus Infection on Second Cancer Development in Newly Diagnosed Myeloma Patients Treated with Lenalidomide in the UK NCRI Myeloma XI Trial. In: Blood. 65th ASH Annual Meeting and Exposition, 09-12 Dec 2023, San Diego, USA. American Society of Hematology , pp. 3366-3368.

Seymour, F., Taylor, C., Gilson, S. et al. (10 more authors) (2023) Senescent Immune Signature in Frail and Vulnerable Newly Diagnosed Myeloma Patients: A Cohort Analysis from the UK-MRA Myeloma XIV Fitness Study. In: Blood. 65th ASH Annual Meeting, 09-12 Dec 2023, San Diego, CA, USA. American Society of Hematology , p. 6602.